Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

Ben Newman, 40, from Tamworth, who is facing eviction from his spot in the Staffordshire's town centre, starts his day at 4am ...

Valeo Financial Advisors LLC bought a new stake in argenx SE (NASDAQ:ARGX – Free Report) during the 4th quarter, according to ...

Reflecting these positive developments, Goldman Sachs has raised its 12-month target price for Everest Medicines to HK$48.32, nearly doubling from the previous HK$24.50. The upgrade factors in ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

However, it is still unknown whether KX is safe and effective for idiopathic membranous nephropathy (IMN) and its therapeutic mechanism of action is unclear. Methods: We conducted a retrospective ...

Specifically, this antibody has been used to treat membranous nephropathy, cryoglobulinemic glomerulonephritis, systemic lupus erythematosus (SLE) and ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA ...